stockrowTango Therapeutics, Inc.
TNGX Healthcare Biotechnology
Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024.
- Revenue
- −100.0%
- EPS
- −5.71%
- Free cash flow
- −4.58%
Quarter to June 2026, against a year earlier
Follow TNGX
Alert me
Tango Therapeutics, Inc. (TNGX) Net margin
Tango Therapeutics, Inc.'s net margin over the twelve months to 30 June 2026 was 0.00%, up 162.8 percentage points from fiscal 2025 (−162.9%). Over the past ten years it has ranged from −678.8% (fiscal 2020) to −157.2% (fiscal 2021); the current reading is higher than 83% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | −162.9% | 146.88 |
| FY2024 | −309.7% | (31.19) |
| FY2023 | −278.5% | 156.60 |
| FY2022 | −435.1% | (277.93) |
| FY2021 | −157.2% | 521.63 |
| FY2020 | −678.8% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 0.00% | 0.00 |
| Mar 2026 | 0.00% | 0.00 |
| Dec 2025 | 0.00% | (29.52) |
| Sep 2025 | 29.5% | 1,250.93 |
| 21 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 30.1% |
| XENE Xenon Pharmaceuticals Inc. compare | 0.00% |
| IRON Disc Medicine, Inc. compare | 0.00% |
| EWTX Edgewise Therapeutics, Inc. compare | 0.00% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| TNGX Tango Therapeutics, Inc. | 0.00% |
| IOVA Iovance Biotherapeutics, Inc. compare | −58.2% |
| ABCL AbCellera Biologics Inc. compare | −248.8% |
| RLAY Relay Therapeutics, Inc. compare | −2,594.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on TNGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement